CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024

This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the use of CAR T-cells in the treatment of HRMM. They highlight clinical trial findings, the use of CAR-Ts in specific high-risk subgroups, and the potential for allogeneic CAR T-cell products. Additionally, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, Ajai Chari, MD, University of California San Francisco, San Francisco, CA, Niels Van de Donk, MD, PhD, VU Amsterdam, Amsterdam, The Netherlands, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, speak about bispecific antibodies in HRMM. They discuss strategies to optimize treatment, potential resistance mechanisms, and combination strategies.